integra-jnj

Integra Acquiring JNJ’s Codman Neurosurgery for $1.05 Billion

Feb 15, 2017 Integra Lifesciences, a prominent medical device maker, has announced that it will acquire the Codman Neurosurgery business of Johnson & Johnson's (JNJ) for $1.05 billion. The Codman unit of JNJ includes a portfolio of medical devices focusing on advanced hydrocephalus, operative neurosurgery, and neuro-critical care, according to the company. During 2016, the acquired products generated approximately $370 million … Continue reading Integra Acquiring JNJ’s Codman Neurosurgery for $1.05 Billion

Advertisements
seattle-1

Seattle Genetics grabs tumor drug of Immunomedics in $2B deal

February 10, 2017 Seat­tle Ge­net­ics has become the new flag car­rier for the solid tumor drug IMMU-132 of   Im­munomedics. In order to claim global rights on the drug, Seat­tle Ge­net­ics is pay­ing $300 mil­lion, and also com­mit­ting up to $1.7 bil­lion more in mile­stones. The biotech will now take the lead on a Phase III … Continue reading Seattle Genetics grabs tumor drug of Immunomedics in $2B deal

johnson & johnson logo

Johnson & Johnson to Purchase Actelion for $30 Billion

Jan 26, 2017 Johnson & Johnson (J&J) has said that it is going to buy Swiss biotech Actelion Pharmaceuticals for $30 billion. The company also plans to spin out its research and development unit into a separate business. The deal is expected to close in mid-February. The companies said in a statement that J&J will pay $280 … Continue reading Johnson & Johnson to Purchase Actelion for $30 Billion

Eli Lilly Logo

Lilly to Acquire CoLucid Pharmaceuticals

Jan. 18, 2017 Eli Lilly and Company and CoLucid Pharmaceuticals, Inc. has announced an agreement for Lilly to acquire CoLucid for $46.50 per share or nearly $960 million. This all-cash transaction will enhance the existing portfolio of Lilly in pain management for migraine. The transaction is expected to close by the end of the first quarter of 2017. CoLucid Pharmaceuticals is a … Continue reading Lilly to Acquire CoLucid Pharmaceuticals

lilly-merck

Lilly and Merck Expand Immuno-Oncology Collaboration

Jan. 11, 2017 Eli Lilly and Company has announced the expansion of an existing immuno-oncology collaboration with Merck, known as MSD outside the U.S. and Canada, to add a new study of LARTRUVO™ (olaratumab) of Lilly with Merck’s KEYTRUDA® (pembrolizumab) in patients with previously treated advanced or metastatic soft tissue sarcoma (STS). Especially, the U.S. Food and Drug Administration (FDA) recently approved LARTRUVO … Continue reading Lilly and Merck Expand Immuno-Oncology Collaboration

amgen-immatics

Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies

Jan. 9, 2017 Amgen and Immatics Biotechnologies, a leading company in the field of cancer immunotherapy, have announced a research collaboration and exclusive license agreement for developing next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers. The collaboration will combine Amgen's validated Bispecific T-cell Engager (BiTE®) technology with Immatics' world-leading XPRESIDENT® target discovery and T-cell receptor (TCR) capabilities with the goal … Continue reading Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies

ipsen

Ipsen Acquiring Oncology Assets from Merrimack Pharmaceuticals

January 9, 2017 Ipsen will gain exclusive commercialization rights for the current and potential future of ONIVYDE indications in the U.S. ONIVYDE is an FDA-approved and clinically differentiated product for treating metastatic pancreatic cancer in adult patients. The transaction also includes the commercial and manufacturing infrastructure of Merrimack, and generic doxorubicin HCl liposome injection. The transaction … Continue reading Ipsen Acquiring Oncology Assets from Merrimack Pharmaceuticals

allergan-lti-assem

Allergan partnerships with Assembly Biosciences and Lysosomal Therapeutics

Jan. 10, 2017 Allergan has announced that it has reached separate agreements to partner with both Lysosomal Therapeutics and Assembly Biosciences for research and development. These announcements were released at the J.P. Morgan Healthcare Conference 2017. Partnering with Lysosomal Therapeutics bolsters the pipeline of Allergan for neurodegenerative diseases. The deal also provides Allergan an option to buy the newly … Continue reading Allergan partnerships with Assembly Biosciences and Lysosomal Therapeutics

takeda logo

Takeda acquires Ariad in $5.2B deal

Takeda, a prominent Japanese drugmaker, provided the first major deal of the J.P. Morgan Healthcare Conference. The company announced a takeover of Ariad Pharmaceuticals which valued the cancer specialist at $5.2 billion. Takeda has been trying relentlessly to improve its oncology products and pipeline. From the deal, the key assets it gains are brigatinib, a treatment in … Continue reading Takeda acquires Ariad in $5.2B deal

bristol-calithera

BMS and Calithera Announce Clinical Collaboration to Evaluate nivolumab in combination with CB-839 for Renal Cell Carcinoma

December 21, 2016 Bristol-Myers Squibb Company and Calithera Biosciences, Inc., a clinical stage biotechnology company focused on discovering and developing new small molecule drugs directed against tumor metabolism and tumor immunology targets for treating cancer, have announced a clinical trial collaboration to evaluate the Opdivo of Bristol-Myers Squibb in combination with  CB-839 of Calithera in patients with … Continue reading BMS and Calithera Announce Clinical Collaboration to Evaluate nivolumab in combination with CB-839 for Renal Cell Carcinoma